Despite its broad growth inhibitory activity, ADT-007 displayed exquisite target specificity, as cancer cells with WT RAS but downstream BRAF mutations, as well as cells from normal tissue, were essentially insensitive to ADT-007. Here, BRAF is linked to cancer.